A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease
Phase of Trial: Phase II
Latest Information Update: 18 May 2010
At a glance
- Drugs Alemtuzumab (Primary) ; Methylprednisolone; Prednisone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 18 May 2010 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
- 10 Jun 2008 The expected completion date for this trial is now 1 May 2008 as reported by ClinicalTrials.gov.